Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD
| Autor: | Wei Shen, Linwen Zhu, Shibo Wu, Hang Chen, Yinyu Mu, Ni Li, Kaitai Liu, Saiqi Ni, Menglu Sang, Guodong Xu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Aging
Lung Neoplasms T-Lymphocytes medicine.medical_treatment T cell Adenocarcinoma of Lung Gefitinib Biomarkers Tumor medicine Humans CTLA-4 Antigen long noncoding RNA prognostic signature Lung cancer Hepatitis A Virus Cellular Receptor 2 B-Lymphocytes tumor immune microenvironment business.industry Macrophages Cancer infiltration of immune cell Cell Biology Immunotherapy Cell cycle Prognosis lung adenocarcinoma Actin cytoskeleton medicine.disease Gene Expression Regulation Neoplastic medicine.anatomical_structure Cancer research Adenocarcinoma RNA Long Noncoding business Research Paper medicine.drug |
| Zdroj: | Aging (Albany NY) |
| ISSN: | 1945-4589 |
| DOI: | 10.18632/aging.203455 |
| Popis: | The tumor immune microenvironment of lung cancer is associated with prognosis and immunotherapy efficacy. Long noncoding RNAs are identified as prognostic biomarkers associated with immune functions. We constructed a signature comprising differentially expressed immune-related lncRNAs to predict the prognosis of patients with lung adenocarcinoma. We established the immune-related lncRNA signature by pairing immune-related lncRNAs regardless of expression level and lung adenocarcinoma patients were divided into high- and low-risk groups. The prognosis of patients in the two groups was significantly different; The immune-related lncRNA signature could serve as an independent lung adenocarcinoma prognostic indicator. The signature correlated negatively with B cell, CD4+ T cell, M2 macrophage, neutrophil, and monocyte immune infiltration. Patients with low risk scores had a higher abundance of immune cells and stromal cells around the tumor. Gene set enrichment analysis showed that samples from low-risk group were more active in the IgA production in intestinal immune network and the T and B cell receptor signaling pathway. High-risk groups had significant involvement of the cell cycle, DNA replication, adherens junction, actin cytoskeleton regulation, pathways in cancer, and TGF-β signaling pathways. High risk scores correlated significantly negatively with high CTLA-4 and HAVCR2 expression and higher median inhibitory concentration of common anti-tumor chemotherapeutics (e.g., cisplatin, paclitaxel, gemcitabine) and targeted therapy (e.g., erlotinib and gefitinib). We identified a reliable immune-related lncRNA lung adenocarcinoma prognosis model, and the immune-related lncRNA signature showed promising clinical prediction value. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|